Focus on...

Dark spots, dull complexion, loss of uniformity

Img_Dark spots, dull complexion, loss of uniformity

8 out of 10 women suffer from complexion irregularities*. Considered as an obstacle in the quest for beauty, more and more women faced with this disorder are consulting their dermatologist. In response to this growing concern, La Roche-Posay developed PIGMENTCLAR, the new anti-dark spot, anti-dull complexion range which offers dermatological correction with lasting results**.

* Interviews of 263 women aged between 30 and 50 years old** Serum anti-dark spot efficacy maintained for up to 3 weeks after use cessation (12 weeks' use) - Cosmeto-clinical study on 31 subjects.


Dark spots and pigmentation defects on the face, neck and lower neckline.

Most of the time these dark spots are harmless, but they are associated with ageing. These enemies of a blemish-free complexion develop mainly on the face, neck and neckline.
Thanks to an ambitious research programme we now have access to more information about dark spots; L'Oréal has discovered new evidence which confirms that dark spots do not solely originate at the epidermal surface. Changes within the melanotope (the melanocyte environment within the epidermis, but also the dermis and the dermo-epidermal junction) also lead to the development of dark spots.

In figures


  • 10 years older* than their real age; this is the impact that pigmentation disorders can have on a woman's appearance.
  • half of women are embarrassed, or very embarrassed by dark spots**.

* Source: Bernhard Fink from department for sociology/anthropology/, institute for zoology and anthropology, university of Göttingen, Germany. Karl Grammer from the ludwig-boltzmann-institute for urban ethology, c/o department for anthropology, a-1090 Vienna, Austria. Paul J.Matts from P&G beauty, rusham park technical centre, whitehall lane, egham, kt15 2ht surrey, United Kingdom.
** Call back Mela-D 2011

LA ROCHE-POSAY's solution

Selecting the best molecules, formulated at active concentrations.

On the basis of this new discovery, La Roche-Posay Laboratories developed PIGMENTCLAR, the new dermatological corrector which offers long-lasting efficacy*. PIGMENTCLAR contains the best molecules in active concentrations which allow it to correct dark spots, a dull complexion and loss of skin uniformity with long-lasting results*.

  • PhE-Resorcinol
100 times more effective than Kojic Acid** and just as effective as the reference medical active ingredient***, PhE-Resorcinol is combined with Ferulic Acid and Ginkgo which complete its action due to their powerful anti-oxidising properties.

  • LHA
Lipo-Hydroxy-Acid, a flagship active ingredient from La Roche-Posay Laboratories, has for the first time been combined with PhE-Resorcinol. Its exfoliating action is 4 times better than that of salicylic acid****, and is ideal for improving the appearance of dark spots while respecting sensitive skin.

  • Niacinamide combined with LHA
Recent studies have demonstrated that LHA also acts by strengthening the extracellular matrix. As for Niacinamide, it works to soothe the epidermal environment around the melanocytes.

Clinical tests have proven the efficacy of this unprecedented formula. Its action on the complexion was demonstrated from first application. And for the first time, long-lasting efficacy against dark spots is observed several weeks after ceasing use of the product*.

* Serum anti-dark spot efficacy maintained for up to 3 weeks after use cessation (12 weeks' use) - Cosmeto-clinical study on 31 subjects.
** in vitro measurements under test conditions of minimum PhE-Resorcinol and Kojic Acid concentrations needed for a 50% reduction in melanin expression within the basal layer in a co-culture of melanocytes and keratinocytes.
Comparison of performances in UV-induced pigmentation protocol study (0.3% PhE-resorcinol + 0.3% LHA is equivalent to 4% Hydroquinone).
**** Lévêque et al., 1995. Mechanism of action of a lipophilic derivative of salicylic acid on normal skin. Skin Research and Technology. Volume 1, Issue 3, pages 115–122.

In figures


  • 4 weeks after application* of PIGMENTCLAR SERUM, a significant reduction in the intensity of actinic lentigos can already be observed.
  • 3 weeks after ceasing application (after 12 weeks of application), the serum remains effective.
* Cosmeto-clinical study on 31 subjects.

Practical aspects

A shock serum treatment and an eye corrector

The serum, which should be applied in the morning or evening to the entire face and neckline, is a shock treatment: it offers quick complexion uniformity, intense dark spot correction and, for the first time, long-lasting efficacy*. Its light, moisturising texture promotes active ingredient absorption. Day after day, dark spots are corrected with lasting results*, and the complexion becomes more uniform and brighter.

The eye contour should be applied morning and evening**. It significantly reduces the two types of under-eye circles: blue circles caused by poor circulation and brown circles linked to the overproduction of melanin. Enriched with light-reflecting pigments, its texture works alongside the cooling metal applicator to instantly illuminate the eyes.

* Serum anti-dark spot efficacy maintained for up to 3 weeks after use cessation (12 weeks' use) - Cosmeto-clinical study on 31 subjects.
** A first for La Roche-Posay

Recommended for you

La Roche-Posay recommends

See all products